Ampio Pharmaceuticals has obtained regulatory approval from the Drugs Controller General of India (DCGI) of the Central Drugs Standard Control Organization (CDSCO) to commence the Phase II AP-019 clinical trial of inhaled Ampion in the country.

A lead drug of Ampio, Ampion is an immunomodulatory agent possessing anti-inflammatory effects.

It disrupts the hyperactive immune response linked to Covid-19 and can potentially boost the clinical outcome in patients suffering from its complications.

The inhaled administration of Ampion aids the drug to directly target and reduce inflammation in the lungs, Ampio noted.

It will be used in the double-blind, placebo-controlled Phase II trial to treat individuals with Covid-19-associated respiratory distress.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The move comes after the Subject Expert Committee (SEC) established by the DCGI approved the AP-019 treatment protocol without recommending changes, Ampion noted.

Ampio president and CEO Mike Macaluso said: “More than a year and a half into the pandemic, healthcare practitioners still lack effective and easy-to-use therapies to treat the severe and often fatal respiratory distress experienced by many Covid-19 patients.

“We are grateful for the DCGI’s swift attention and believe their decision underscores the critical medical need for Ampion as a potential treatment option.”

The commencement of the Phase II trial of inhaled Ampion follows robust strong top-line data obtained from its Phase I AP-014 trial.

In April 2021, the company reported that the Phase I trial failed to meet its primary goal of safety and tolerability.

However, according to the top-line results, the drug was demonstrated to reduce all-cause mortality in Covid-19 respiratory distress by 78% as against the standard of care (SOC) for subjects with Covid-19-linked respiratory distress.

Furthermore, only 5% mortality was observed in subjects receiving SOC plus Ampion versus 24% in the SOC arm.